Ensuring Access to Essential Drugs Act
- Bill Number
- H.R. 1922
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-06: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-02-13T21:03:05Z
Official Summary
Ensuring Access to Essential Drugs Act
This bill exempts certain brand-name drugs from the Medicare Part D Manufacturer Discount Program. Under the program, drug manufacturers provide discounts to beneficiaries who have incurred costs above the annual deductible under the Medicare prescription drug benefit.
Specifically, the bill exempts from the program orally administered, brand-name drugs that are considered generics for purposes of the Medicaid Drug Rebate Program (per an exception granted by the Centers for Medicare & Medicaid Services).
Sponsor
Rep. Garbarino, Andrew R. [R-NY-2]
Cosponsors (2)
Rep. Harshbarger, Diana [R-TN-1], Rep. Suozzi, Thomas R. [D-NY-3]
Recent Actions
- 2025-03-06: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-06: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-06: Introduced in House
- 2025-03-06: Introduced in House
Bill Versions
- Ensuring Access to Essential Drugs Act — issued 2025-03-06 — PDF (2 pages)